National Mediation Board

National Mediation Board

Close: Jan 21, 2026

ADVOCATE’s objective is to revolutionize the management of patients with CVD by enabling the development of a clinically validated, regulatory-compliant, patient-facing, multimodal agentic system to support and deliver clinical care. The agentic system will operate as a unit with two distinct interoperable components, which are the CVD Agent (TA1) and Supervisory Agent (TA2), which will be developed, implemented, and clinically validated with support of healthcare organizations (TA3). TA1 – CVD Agent: TA1 is centered on the development of a clinical AI Agent that provides care management to patients with chronic CVD, such as heart failure and post-myocardial infarction (“heart attack”). This CVD Agent will interact directly with patients either through a mobile app or regular phone/text. It will leverage patient’s inputs and data to perform advanced clinical reasoning. This clinical AI Agent will function in with direct control and in coordination with the patient’s trusted healthcare providers. It will operate as an extension of the clinical team with the ability to adapt its functions to the context in which the healthcare is provided. The CVD Agent will work to achieve the goals set by the clinical team while dynamically adapting to the patient’s preferences. See attached file.

National Mediation Board

Close: Mar 26, 2026

The IV&V partner will be a commercial entity that will support the government’s Program Management Team to assess the performing teams’ progress, as required by the government. This commercial entity must be technically, managerially, and financially independent of all developmental performing teams. An IV&V partner will ensure reproducibility and credibility of data generated by Performers at critical assessment points throughout the program. Additionally, IV&V will supply government-selected cell types to Performers to be used for technology demonstrations. Proposers selected to receive funding related to research and development under TA1 or TA2 are not eligible to work as an IV&V partner. See attached file.

National Mediation Board

Close: Dec 5, 2025

Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) imitative as a method to efficiently fund innovative solutions in support of HHS and ARPA-H objectives.